ArcticZymes Technologies Reports Q3 2026 Financial Results

ArcticZymes Technologies reported Q3 2026 revenue growth of 15% year over year, or 24% at constant currency, driven mainly by demand in its biomanufacturing and CDMO segments. Nine-month EBITDA was NOK 12.1 million. Management said recently launched RNA enzymes could provide a new growth platform, while foreign-exchange movements and timing remained headwinds.